UPDATE: Concert Pharmaceuticals Shares Up 8.42%; Earlier UBS Rasied Price Target From $22 to $34 Citing Strength Of Clinical Candidates And Underestimated Probability Of Success For CTP-543 Treatment
Hal Lindon